JP Morgan Chase’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-172,658
| Closed | -$2.58M | – | 7557 |
|
|
2022
Q4 | $2.58M | Buy |
172,658
+172,558
| +172,558% | +$2.39M | ﹤0.01% | 3372 |
|
|
2022
Q3 | $1K | Buy |
100
+5
| +5% | +$38 | ﹤0.01% | 6411 |
|
|
2022
Q2 | $1K | Hold |
95
| – | – | ﹤0.01% | 6419 |
|
|
2022
Q1 | $1K | Hold |
95
| – | – | ﹤0.01% | 6529 |
|
|
2021
Q4 | $0 | Hold |
95
| – | – | ﹤0.01% | 7298 |
|
|
2021
Q3 | $1K | Hold |
95
| – | – | ﹤0.01% | 6437 |
|
|
2021
Q2 | $1K | Sell |
95
-8,153
| -99% | -$56.2K | ﹤0.01% | 6298 |
|
|
2021
Q1 | $60K | Sell |
8,248
-96,978
| -92% | -$837K | ﹤0.01% | 5499 |
|
|
2020
Q4 | $607K | Buy |
105,226
+59,954
| +132% | +$343K | ﹤0.01% | 4266 |
|
|
2020
Q3 | $262K | Buy |
45,272
+40,696
| +889% | +$201K | ﹤0.01% | 4241 |
|
|
2020
Q2 | $24K | Buy |
+4,576
| New | +$28.9K | ﹤0.01% | 5006 |
|
|
2019
Q2 | – | Sell |
-2,615
| Closed | -$21K | – | 6146 |
|
|
2019
Q1 | $21K | Sell |
2,615
-123
| -4% | -$1.27K | ﹤0.01% | 5404 |
|
|
2018
Q4 | $44K | Buy |
2,738
+332
| +14% | +$7.3K | ﹤0.01% | 5130 |
|
|
2018
Q3 | $80K | Buy |
2,406
+342
| +17% | +$8.79K | ﹤0.01% | 5032 |
|
|
2018
Q2 | $47K | Sell |
2,064
-9,328
| -82% | -$221K | ﹤0.01% | 5102 |
|
|
2018
Q1 | $330K | Sell |
11,392
-42,061
| -79% | -$1.23M | ﹤0.01% | 4186 |
|
|
2017
Q4 | $1.49M | Buy |
+53,453
| New | +$1.66M | ﹤0.01% | 3493 |
|
|
2013
Q4 | – | Sell |
-5,488
| Closed | -$113K | – | 4325 |
|
|
2013
Q3 | $113K | Buy |
5,488
+1,168
| +27% | +$26.7K | ﹤0.01% | 4158 |
|
|
2013
Q2 | $109K | Buy |
+4,320
| New | +$185K | ﹤0.01% | 4142 |
|
JP Morgan Chase's AVEO Position: Q1 2023 in Review
JP Morgan Chase sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 172,658 shares — an estimated $2.58M sold.
JP Morgan Chase first reported a position in AVEO in Q2 2013 and held it in 19 quarters. The position peaked at $2.58M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- JP Morgan Chase reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- JP Morgan Chase sold 172,658 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.58M.
- JP Morgan Chase first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 19 quarters.
- JP Morgan Chase's AVEO Pharmaceuticals, Inc. position peaked at $2.58M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.